This Phase 2a proof of concept (PoC) study is a 24-week Induction and Maintenance Period and a 72-week Long-Term Extension Period treat-through design study that utilizes a platform framework. The study will evaluate the clinical efficacy and safety of targeted therapies (TaTs) in moderate to severe CD. For the purpose of this protocol, TaTs represent…
mRNA-1403-P301
A Phase 3, Randomized, Observer-blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1403, a Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults ≥18 Years of Age Register Today!
MK-7240-001
To evaluate the efficacy of MK-7240 compared to Placebo as assessed by the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12. Register Today!
MK-7240-008
To evaluate the efficacy of MK-7240 compared to Placebo as assessed by the proportion of participants achieving clinical remission per Modified Mayo Score at Week 52. Register Today!
ANB030-204: Ulcerative Colitis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis Register Today!
mRNA-1283-P301 PART 2 Covid-19
A randomized, observer-blind, active-controlled Phase 3 study to investigate the safety, immunogenicity, and relative vaccine efficacy of mRNA-1283 compared with mRNA-1273 in participants aged ≥12 years for the prevention of COVID-19. Register Today!
B7981080
A phase 3 randomized, double-blind, 52-week placebocontrolled multi-center study with a double-blind 52-week extension period with randomized dose up/dose down titration investigating the efficacy, safety, and tolerability of Ritlecitinib in adult participants with nonsegmental vitiligo. Register Today!
Vaccine (RSV) – 222090 (extension to 212494)
A phase 3b, randomized, open label, multi-country, multi-center, extension and crossover vaccination study to evaluate the immunogenicity and safety of different revaccination schedules and persistence of a single dose of the RSVPreF3 OA vaccine in adults aged 60 years and above who participated in the RSV OA=ADJ-006 study. Register Today!
Atopic Dermatitis – M16-047 (extension to M18-891)
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis For more information, please click here. Register Today!
Alopecia Areata – M23-716
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata Register Today!